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We have investigated the formation of DNA adducts in the bone marrow and white blood cells of
male B6C3F1 mice treated with benzene using P1-enhanced 32P-postlabeling. No adducts were
detected in the bone marrow of controls or mice treated with various doses of benzene once a
day. After twice-daily treatment for 1 to 7 days with benzene, 440 mg/kg, one major (no. 1) and
up to two minor DNA adducts were detected in both the bone marrow and white blood cells. The
relative adduct levels in these cells ranged from 0.06 to 1.46 x 10-7. A significant correlation
(r2 = 0.95) between levels of adducts in bone marrow and white blood cells was observed. After
a 7-day treatment with benzene, 440 mg/kg twice a day, the number of cells per femur
decreased from 1.6 x 107 to 0.85 x 107, indicating myelotoxicity. In contrast, administration of
benzene once a day produced only a small decrease in bone marrow cellularity. The observed
induction of toxicity in bone marrow was paralleled by formation of DNA adducts. In vitro
treatment of bone marrow with hydroquinone (HQ) for 24 hr produced the same DNA adducts as
found after treatment of mice with benzene, suggesting that HQ is the principal metabolite of
benzene leading to DNA adduct formation in vivo. Using 32P-postlabeling the principal DNA
adduct formed in vivo was compared with N2-(4-hydroxyphenyl)-2'-deoxyguanosine-3'-phosphate.
The results of this comparison demonstrates that the DNA adduct formed in vivo
co-chromatographs with N2-(4-hydroxyphenyl)-2'-deoxyguanosine-3'-phosphate. These studies
indicate that metabolic activation of benzene leads to the formation of DNA adducts in bone
marrow and white blood cells and suggest that measurement of DNA adducts in white blood
cells may be an indicator of biological effect following benzene exposure. Environ Health
Perspect 104(Suppl 6):1 189-1193 (1996)
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Introduction
Benzene is widely used in the chemical
industry as an intermediate in the produc-
tion ofother agents and as a fuel additive; it
is also found in automobile exhaust and
cigarette smoke (1). Thus, human exposure
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myelotoxicity, DNA adducts, exposure,
to benzene occurs from a variety ofsources
(1). Concern regarding this compound
arises from evidence that acute exposure to
benzene is leukemogenic in humans (2,3).
After absorption, benzene is initially
metabolized in the liver by cytochrome 2E1
(4-7). Results from microsomal activation
systems and in vivopharmacokinetic studies
have shown that the principal metabolites
of benzene are phenol, hydroquinone
(HQ), muconaldehyde, and catechol
(CAT) (8-10). HQ and CAT accumulate
in the bone marrow (11,12), where they
are further activated to exert their myelo-
toxic effects (6). Evidence for further acti-
vation of these metabolites by peroxidases
(13-15) and prostaglandin H-synthase
(16) has been presented.
Our studies of the activation of HQ,
CAT, and 1,2,4-benzenetriol (BT) to form
DNA adducts in HL-60 cells, mouse bone
marrow macrophages, and human bone
marrow (17-19) have shown a good corre-
lation between cytotoxicity and the level of
DNA adducts formed by the individual
metabolites and between cellular peroxi-
dase activity and DNA adduct formation
after treatment with HQ (19). In contrast
to these in vitro findings, evidence for the
formation of DNA adducts in animals
treated with benzene has been contradic-
tory. Dose-dependent binding of radiola-
beled benzene to DNA, RNA, and protein
in various tissues ofmice and rats has been
reported (20-22). 32P-Postlabeling studies
by Bauer et al. (23) have demonstrated
DNA adduct formation in the liver ofrab-
bits treated with benzene; however, Reddy
et al. (24-26) were unable to detect the
formation of DNA adducts in various tis-
sues of either Sprague-Dawley rats or
B6C3F1 mice administered benzene or its
hydroxylated metabolites.
The purpose of the present study was
to investigate the formation of DNA
adducts and myelotoxicity in the bone
marrow and white blood cells of B6C3F1
mice treated with benzene.
Results
DNAAdductFormation in Vivo
Male B6C3F1 mice were given injections
of benzene (99.9%; Aldrich Chemical
Company, Milwaukee, WI) dissolved in
corn oil (25-880 mg/kg) either once a day
for 1 to 14 days or twice a day by ip injec-
tion at 8-hr intervals for 1 to 7 days (27).
Controls received an equal volume ofcorn
oil. Following treatment, the animals were
anesthetized and blood and bone marrow
were collected. The levels ofDNA adducts
in these tissues were investigated using P1-
enhanced 32P-postlabeling (17-19,27). The
presence of DNA adducts was very depen-
dent upon the benzene treatment schedule.
No DNA adducts were found in the bone
marrow of mice treated once a day with
benzene (Table 1; Figure 1A) or in controls
(Figure iB). Twice-daily treatment with
benzene, 440 mg/kg, for one day produced
a single DNA adduct (Figure 1C) with a
relative adduct level of 0.06 x 10-7 (Table
1). When this treatment was extended to 3
days, one major adduct and two minor
adducts were detected in the bone marrow
of treated mice (Figure ID). The relative
adduct level produced by this treatment
procedure was 0.58 x 10-7 and the distribu-
tion ofthe adducts was 76, 12, and 12% for
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Table 1. Adduct levels in bone marrow of mice treated with various doses of benzene.a
Benzene dose, Treatment schedule, Adduct level, Distribution, %
mg/kg no. doses/no. days x 10-7 1 2 3
25 1/7 ND
25 1/14 ND
50 1 for 7 days ND
50 1/14 ND
440 1/1 ND
440 1/3 ND
880 1/1 ND
880 1/3 ND
100 2/3 0.13± 0.02 100
250 2/3 0.22 ± 0.09 75 8.9 16.4
440 2/1 0.06±0.02 100
440 2/3 0.58± 0.08 76.5 11.9 11.6
440 2/5 0.89±0.16 74.9 14.7 11.1
440 2/7 1.46±0.26 69.4 17.2 13.4
ND, adducts not detected. aEach value is the mean ± SD of 5 to 11 experiments.
Ie
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....0.
Figure 1. Detection of benzene-DNA adducts in the bone marrow of B6C3F1 mice treated ip with various doses of
benzene. (A)3 days of treatment with benzene, 440 mg, once a day; (B)vehicle-treated mice (controls); (C) 1 day of
treatment with benzene, 440 mg/kg, twice a day; (D)3 days of treatment with 440 mg/kg of benzene twice a day.
The autoradiograms were exposed at-70°C for 14 hr.
adducts 1, 2, and 3, respectively (Table 1).
With twice-daily treatment the formation
ofDNA adducts by benzene was both dose
and time dependent (Table 1).
In parallel studies the formation of
DNA adducts in white blood cells of
B6C3F1 mice after administration of
benzene was investigated. Twice-a-day
treatment with 440 mg/kg ofbenzene for 3
days resulted in the formation ofthe same
DNA adduct pattern as observed in bone
marrow of the treated animals (Figure 2).
The relative adduct level produced by this
treatment was 0.73 x 10-7. Similar to the
results with bone marrow, the levels of
DNA adducts in the white blood cells were
dependent on both dose and length of
treatment time with benzene and were sig-
nificantly correlated with the levels ofDNA
adducts in the bone marrow (r2 = 0.97,
p<0.001) (G Levay, unpublished results).
Effects on BoneMarrowCellularity
Once-daily administration of benzene, 25
or 50 mg/kg, did not affect bone marrow
cellularity; administration of benzene at
higher concentrations (440 or 880 mg/kg)
for up to 3 days produced a small decrease
in bone marrow cellularity (Table 2).
Twice-daily treatment with benzene,
440 mg/kg, for 1, 3, 5, and 7 days resulted
in a statistically significant decrease in bone
marrow cellularity for each treatment time.
The number of cells per femur decreased
from 1.59 x 107 in controls to 0.84 x 107
after 7 days oftreatment (Table 2).
Figure 2. Detection of benzene-DNA adducts formed
in white blood cells of B6C3F1 mice following twice-
daily ip treatment with 44D mg/kg benzene for 3 days.
Films were exposed at -70'C for 24 hr.
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Table 2. Cellularity of mouse bone marrow treated with benzene.a
Benzene dose,
mg/kg Dose/day Days of treatment Bone marrow cells/femur, x 107
Control 1.59 ±0.09
25 1 7 1.5(1)
25 1 14 1.45(1)
50 1 7 1.45(1)
50 1 14 1.43(1)
440 1 1 1.47± 0.05 (3)
440 1 3 1.45 (2)
880 1 1 1.45 ± 0.04 (3)
880 1 3 1.45 (2)
440 2 1 1.48 ±0.06b
440 2 3 1.13±0.04c
440 2 5 1.05 ±0.07c
440 2 7 0.84± 0.06c
"Values in parentheses are number of determinations; all other values represent the mean ± SD of six to eight
analyses. bp<0.05 versus control. cp<0.001 versus control.
.I
A
Figure 3. (A)Detection of DNA adducts in bone marrow of B6C3F1 mice treated in vitrowith 250 pr\
(B)co-chromatography of DNA adducts detected in the bone marrow of mice treated in vitro with 2
24 hrwith the DNA adducts detected in the bone marrow of mice treated for 440 mg/kg of benzene 1
3 days.
In VtroStudies ofAdductFormation
In vitro treatment of mouse bone marrow
with 250 pM of HQ for 24 hr produced
three DNA adducts (Figure 3A). The aver-
age relative adduct level was 1 x 10-7, and
the distribution ofthe adducts was 40, 37,
and 22 for adducts 1, 2, and 3, respec-
tively. Co-chromatography experiments
showed that these adducts were the same as
those formed after in vivo exposure to ben-
zene (Figure 3B).
Structure ofDNAAdductForned
in Vivo
Previous studies have investigated the
DNA adducts formed by the reaction of
p-benzoquinone (BQ) with purified DNA.
Three DNA adducts were detected by
32P-postlabeling (17,28,29). Structural
analysis and 32P-postlabeling ofthe isolated
products allowed identification of the
DNA adducts as (3'-hydroxy)-
zetheno-2'-deoxycytidine-3'-
(no. 2), (3'-hydroxy)-1,N6-be
2'-deoxyadenosine-3'-phospha
and (3'-hydroxy)-1,N2-bei
2'-deoxyguanosine-3'-phosph;
(17,28,29). However, compari
chromatography of these ident
adducts with the DNA adduct
HL-60 cells treated with either I
demonstrated that the cellt
adducts were different from t]
formed in purified DNA (17)
reaction ofguanosine-3'- phos
BQ at pH 1, we have isolated
corresponding to N2-(4-hydro
guanosine-3'-phosphate. Pr
studies demonstrated that this f
chromatographed with the DI
formed in HL-60 cells after HC
of (30). As an extension of th(
Figure 4. (A) Autoradiogram of 32P-postlabeling of N2-
B4-hydroxyphenyl)-2'-deoxyguanosine-3'-phosphate;
B (B) rechromatography analysis of N2-(4-hydroxyphenyl)-
2'-deoxyguanosine-3'-phosphate with adduct 1 formed
in B6C3F1 mice treated twice a day with 440 mg/kg of
A HQ for 24 hr; benzene for 3 days: Lane 1, DNA adduct 1; lane 2, 1:1
250 pM HQ for mixture of DNA adduct 1 and N2-(4-hydroxyphenyl)-2'-
twice a dayfor deoxyguanosine-3'-phosphate; lane 3, N2-(4-hydroxy-
phenyl)-2'-deoxyguanosine-3'-phosphate. The exposure
times for A and Bwere 10 min at room temperature and
-3,N4-ben- overnight at -70°C, respectively.
phosphate
-nzetheno-
te (no. 3), we have prepared N2-(4-hydroxyphenyl)-
nzetheno- 2'-deoxyguanosine-3'-phosphate (30) and
ate (no. 1) analyzed it by32P-postlabeling (Figure 4A).
ison by co- DNA isolated from the bone marrow of
:ified DNA benzene-treated mice was postlabeled and
formed in the adducts were resolved on PEI-cellulose
BQ or HQ, sheets (J.T. Baker Inc, Phillipsburg, NJ)
ular DNA and located by autoradiography. DNA
he adducts adduct 1 was eluted from the PEI-cellulose
. From the sheets. Similar procedures were applied to
;phate with 32P-postlabeled N2-(4-hydroxyphenyl)-2'-
a product deoxyguanosine-3'-phosphate. Rechro-
xyphenyl)- matography experiments to compare the
reliminary DNA adducts showed that DNA adduct 1
product co- formed in the bone marrow of benzene-
NA adduct treated mice had the same chromatographic
2 treatment mobility as N2-(4-hydroxyphenyl)-2'-
ose studies, deoxyguanosine-3'-phosphate (Figure 4B).
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Conclusion
Evidence for the formation ofDNAadducts
in vivo following benzene administration
has been contradictory. In our investiga-
tions we have shown that treatment of
B6C3F1 mice with benzene results in the
formation of DNA adducts in the bone
marrow and white blood cells as detected
by 32P-postlabeling. Adduct formation was
dependent on both the dose and duration
of treatment. Linear increases in DNA
adduct formation were observed after treat-
ment of B6C3F1 mice with 100 to 440
mg/kg of benzene twice a day. These
results are in agreement with the findings
ofMcDonald (31), who also demonstrated
linear increases in protein adduct forma-
tion in the blood and bone marrow ofmice
treated with benzene.
The formation of DNA adducts was
very schedule dependent. Once-daily
administration ofbenzene did not lead to
the formation ofDNA adducts; however,
adducts were readily detectable after twice-
daily administration ofbenzene. In similar
experiments, Reddy et al. (26) did not
detect DNA adduct formation in bone mar-
row of B6C3F1 mice after single-dose
administration ofbenzene. In contrast to
our results, the binding ofradiolabeled ben-
zene to DNA in various rat tissues after a
single treatment has been reported by sev-
eral laboratories (20-22); however, in these
studies the formation of a specific DNA
adduct has not been demonstrated. The bio-
logical mechanisms responsible for the
schedule dependency of DNA adduct for-
mation are unclear. Previous studies have
shown that the benzene metabolites HQ,
CAT, and 1,2,4-benzenetriol can interact
synergistically to produce increased levels of
DNA adducts (18). The administration of
benzene twice a day may allow this process
to occur.
Once-daily treatment with benzene
produced only a small decrease in bone
marrow cellularity, whereas twice-daily
treatment reduced cellularity by 50%.
Comparison of the dose-dependent for-
mation of DNA adducts in white blood
cells and bone marrow with that of the
loss in bone marrow cellularity showed an
extremely good correlation (r2 = 0.99,
p<0.001) between these end points.
Although these results would indicate that
measurement of DNA adducts in white
blood cells may be useful as a dosimeter of
benzene exposure, they have to be consid-
ered together with our observation that no
DNA adducts were detected after once-
a-day administration of benzene. These
data taken together suggest that the for-
mation of DNA adducts in white blood
cells may be a better indicator ofa biolog-
ical effect than a molecular dosimeter of
benzene exposure.
In addition to DNA adduct formation,
the formation ofoxidative base damage as
measured by 8-hydroxy-2'-deoxyguanosine
has been detected in the bone marrow of
mice treated in vivowith benzene (32) and
following in vitro activation ofthe hydrox-
ylated benzene metabolites (QP Ye,
unpublished results). The contribution of
oxidative base damage and DNA adducts
to the carcinogenic and leukemogenic
effect of benzene remains to be defined.
However, it is possible that both of these
forms of DNA damage contribute to the
induction of mutations and chromosomal
breakage and rearrangements observed
after benzene administration (33).
In vitro treatment of mouse bone
marrowwith HQresulted in a DNA adduct
pattern similar to that observed in the bone
marrow after in vivo treatment with
benzene. Previous studies have shown that
adduct 1 was the same in purified mouse
bone marrow macrophages and human bone
marrow treated with HQ (19). These results
suggest that HQ is the principal metabolite
ofbenzene leading to DNA adduct forma-
tion in bone marrow. Several lines of evi-
dence suggest that peroxidase enzymes in
bone marrow activate HQ to form the
DNA adducts detected. In vitro, benzene
metabolites can serve as reducing cosub-
strates for peroxidase enzymes (13-15), and
incubation of HQ with myeloperoxidase,
H202, and purified DNA results in adduct
formation (D Pathak, unpublished result).
In addition, the level of DNA adduct for-
mation in cells treated with HQ correlates
positively with the levels ofcellular peroxi-
dase activity (19). These results support the
general model ofperoxidase activation of
HQto form DNAadducts (19,34).
The structure of the DNA adduct
formed in bone marrow following benzene
administration was investigated. Previous
studies have compared the DNA adduct
formed in HL-60 cells treated with HQ
with the DNA adducts formed by reaction
ofBQwith DNA and found that the DNA
adducts formed in HL-60 cells did not cor-
respond to the benzetheno-DNA adducts
(17,34). In the present study we have
found that the DNA adduct formed in vivo
after benzene administration co-chro-
matograhed with N2-(4-hydroxyphenyl)-
2'-deoxyguanosine-3'-phosphate. Further
studies are required to confirm the structural
identification ofthis DNAadduct.
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